Primary source: Health Sciences Authority
New mandatory safety reporting and record-keeping requirements for suppliers of Complementary Health Products (CHPs) in Singapore are proposed under the Health Products Act.
These requirements will strengthen the oversight of CHP products, ensuring better safety and quality standards which could impact compliance workflows for suppliers.
Suppliers must implement new protocols for safety reporting and record-keeping as per the proposed framework.
Regulatory Intelligence Lead
Review before 2026-07-29.
Proposed requirements for Product Notification, Record Keeping, and Safety Reporting for CHPs.
Suppliers of CHPs in Singapore may face new mandatory safety reporting and record-keeping requirements under the proposed framework.
Suppliers must implement new protocols for safety reporting and record-keeping as per the proposed framework.
The Health Sciences Authority (HSA) of Singapore has opened a consultation on a proposed regulatory framework aimed at enhancing the safety and quality oversight of Complementary Health Products (CHP). This includes new mandatory requirements for Product Notification, Record Keeping, and Safety Reporting. The deadline for feedback is July 29, 2026.
What changed: New mandatory safety reporting and record-keeping requirements for suppliers of Complementary Health Products (CHPs) in Singapore are proposed under the Health Products Act.
Why it matters: These requirements will strengthen the oversight of CHP products, ensuring better safety and quality standards which could impact compliance workflows for suppliers.
Practical implication: Suppliers must implement new protocols for safety reporting and record-keeping as per the proposed framework.
Published from the Firecrawl policy change extraction pipeline.
Implement a gap analysis for 505(b)(2) applications to identify safety data needs and adjust safety monitoring systems as necessary to accommodate new product characteristics.
MAHs and sponsors must enhance their pharmacovigilance systems to monitor microbiome-specific safety issues, comply with established safety standards, and address concerns related to antimicrobial resistance.
Stakeholders, including manufacturers and clinicians, must review and potentially revise their post-market vigilance and safety monitoring protocols in response to the FDA's proposed regulatory approaches for generative AI devices.
Developers of MBMPs must align their safety assessment protocols with the MHRA's expectations and are encouraged to engage with the MHRA early to establish appropriate regulatory strategies.
